Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase

被引:30
作者
Takiguchi, Shunichi [1 ,2 ]
Ayaori, Makoto [1 ]
Uto-Kondo, Harumi [1 ]
Iizuka, Maki [1 ]
Sasaki, Makoto [1 ]
Komatsu, Tomohiro [1 ]
Takase, Bonpei [3 ]
Adachi, Tetsuo [4 ]
Ohsuzu, Fumitaka [2 ]
Ikewaki, Katsunori [1 ]
机构
[1] Natl Def Med Coll, Dept Internal Med, Div Antiaging, Tokorozawa, Saitama 3598513, Japan
[2] Dept Internal Med, Div Cardiol, Tokorozawa, Saitama, Japan
[3] Natl Def Med Coll, Dept Crit Care Med, Tokorozawa, Saitama 3598513, Japan
[4] Gifu Pharmaceut Univ, Lab Clin Pharmaceut, Tokorozawa, Saitama, Japan
关键词
ARB; endothelial dysfunction; EC-SOD; FMD; TYPE-1 RECEPTOR ANTAGONISM; CORONARY-ARTERY-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR OUTCOMES; NITRIC-OXIDE; DYSFUNCTION; INHIBITION; MICROALBUMINURIA; VASODILATION; PREVENTION;
D O I
10.1038/hr.2011.11
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Endothelial dysfunction in essential hypertension is an independent predictor for future cardiovascular events. Although inhibition of the renin-angiotensin system (RAS) reportedly improves endothelial function through its effects on oxidative stress and inflammation, questions remain regarding the factors that are pivotal for improvement of endothelial function by RAS inhibition. We therefore performed a prospective, randomized crossover trial in which an angiotensin II type 1 receptor antagonist, olmesartan and calcium channel blocker, amlodipine, were compared in 31 essential hypertensive patients. Results showed that, although both treatments achieved comparable lowering of blood pressure (BP), olmesartan, but not amlodipine, significantly improved endothelial function as evaluated by flow-mediated vasodilation (FMD) in the brachial artery. Although no significant changes in diabetic and lipid parameters were observed with either drug, olmesartan slightly decreased estimated glomerular filtration rate, which, surprisingly, translated into decreased microalbuminuria. In a similar vein, olmesartan reduced serum C-reactive protein and increased urine antioxidant levels compared with baseline, and reduced urine 8-epi-prostaglandin F2 alpha levels compared with both baseline and amlodipine. Finally, although overall changes in plasma extracellular superoxide dismutase (EC-SOD) levels were not modulated by either treatment, for olmesartan there was a positive correlation between changes in FMD and those in EC-SOD levels. In conclusion, olmesartan improved endothelial function in hypertensive patients independent of its BP-lowering effect, which was due, at least in part, to its antioxidative property. Therefore, olmesartan might provide a greater long-term benefit for hypertensive patients with impaired endothelial function than amlodipine. Hypertension Research (2011) 34, 686-692; doi: 10.1038/hr.2011.11; published online 10 February 2011
引用
收藏
页码:686 / 692
页数:7
相关论文
共 47 条
[1]   QUANTITATIVE-ANALYSIS OF EXTRACELLULAR-SUPEROXIDE DISMUTASE IN SERUM AND URINE BY ELISA WITH MONOCLONAL-ANTIBODY [J].
ADACHI, T ;
OHTA, H ;
YAMADA, H ;
FUTENMA, A ;
KATO, K ;
HIRANO, K .
CLINICA CHIMICA ACTA, 1992, 212 (03) :89-102
[2]  
Al Khalaf MM, 2009, AM J CARDIOVASC DRUG, V9, P29, DOI 10.2165/00129784-200909010-00004
[3]   Essential Hypertension Is There a Role for Inflammatory Mechanisms? [J].
Androulakis, Emmanuel S. ;
Tousoulis, Dimitris ;
Papageorgiou, Nikolaos ;
Tsioufis, Costas ;
Kallikazaros, Ioannis ;
Stefanadis, Christodoulos .
CARDIOLOGY IN REVIEW, 2009, 17 (05) :216-221
[4]   Prevention of loss of renal function over time in patients with diabetic nephropathy [J].
Barnett, A .
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (05) :40S-47S
[5]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[6]   INHIBITION AND STIMULATION OF NITRIC-OXIDE SYNTHESIS IN THE HUMAN FOREARM ARTERIAL BED OF PATIENTS WITH INSULIN-DEPENDENT DIABETES [J].
CALVER, A ;
COLLIER, J ;
VALLANCE, P .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (06) :2548-2554
[7]   Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension [J].
Chrysant, SG ;
Marbury, TC ;
Robinson, TD .
JOURNAL OF HUMAN HYPERTENSION, 2003, 17 (06) :425-432
[8]   Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats [J].
Colonna, VD ;
Rigamonti, A ;
Fioretti, S ;
Bonomo, S ;
Manfredi, B ;
Ferrario, P ;
Bianchi, M ;
Berti, F ;
Muller, EE ;
Rossoni, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 516 (03) :253-259
[9]   Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery - A report of the International Brachial Artery Reactivity Task Force [J].
Corretti, MC ;
Anderson, TJ ;
Benjamin, EJ ;
Celermajer, D ;
Charbonneau, F ;
Creager, MA ;
Deanfield, J ;
Drexler, H ;
Gerhard-Herman, M ;
Herrington, D ;
Vallance, P ;
Vita, J ;
Vogel, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :257-265
[10]   Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients [J].
Derosa, Giuseppe ;
Maffioli, Pamela ;
Salvadeo, Sibilla A. T. ;
Ferrari, Ilaria ;
Gravina, Alessia ;
Mereu, Roberto ;
Palumbo, Ilaria ;
Fogari, Elena ;
D'Angelo, Angela ;
Cicero, Arrigo F. G. .
HYPERTENSION RESEARCH, 2010, 33 (08) :790-795